Sunday , 24 September 2023

4 MedTech Stocks Set To Explode (+2K Views)

The medical devices industry…has seen quite an eventful year in 2017…courtesy of a series of socio-political occurrences that favored the space….[but,] standing at the threshold of 2018, it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more…Based on strong fundamentals and positive vital metrics, the following 4 stocks have ample credential to return more to shareholders amid eco-political threats.

The original article is presented here by in an edited ([ ]) and revised (…) format to provide a fast & easy read.

To save investors from the time-taking process of identifying the powerful MedTech stocks that may brave the industry threats in 2018 we have, with the help of the Zacks Stock Screener, highlighted four MedTech stocks:

  • with market cap of $500 million or more
  • with a  Zacks Rank #1 (Strong Buy) or 2 (Buy)
  • and positive estimate revision trend of more than 5% for fiscal 2018.

1. Bio-Rad Laboratories, Inc. (BIO)

Over the years, this $7300 billion market-cap stock has successfully demonstrated solid top-line growth driven by strong sales of Droplet Digital PCR instruments and consumables, cell biology and food safety products in the life science group. Additionally, the company has a strong cash balance that enables it to carry out share repurchases and provide solid returns to investors. The expansion in gross and operating margin also buoys optimism. The company is also constantly investing in R&D for product innovation.

Based on this bullish sentiment, over the past four weeks the company’s EPS estimate for the upcoming fiscal has improved 6.08%. The stock sports a Zacks Rank #1. 

2. Mazor Robotics Ltd. (MZOR)

Market is particularly upbeat about the company’s CE Mark approval for its Mazor X Surgical Assurance platform. The approval will allow Mazor Robotics and its partner Medtronic to commercialize, co-promote and market the Mazor X platform in countries that recognize CE Mark. This development should get reflected in Mazor’s 2018 performance. This $1384 billon stock has a Zacks Rank #2. Over the past month, estimates for the company have moved 9.57% north for the next fiscal.

3. Tactile Systems Technology, Inc. (TCMD)

This $522-billion company develops and markets at-home therapy devices that treat lymphedema and chronic venous insufficiency. The company’s offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinical staff.

Meanwhile, the figures for Tactile Systems’ next year are quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a 40.4% rise over the said frame. The stock flaunts a Zacks Rank #1.

4. DexCom, Inc. (DXCM)

DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand its product portfolio. In this regard, DexCom announced its collaboration in September 2017 with leading wearables brand Fitbit (FIT) to develop and market products for better management of diabetes and get a clearer picture of overall health with easy-to-use mobile tools.

In November 2017, the company partnered with Eli Lilly and Company (LLY) adding its flagship continuous glucose monitoring system to Lilly’s Connected Diabetes Ecosystem.

This Zacks Rank #2 stock with a market cap of $4.93 billion is a valuable pick for 2018. Over a month, estimates for the company have moved 9.76% north for the next fiscal.